Sara Cuadrado-Castano

Dr. Sara Cuadrado-Castano

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJudit Svensson-Arvelund
Judit Svensson-Arvelund
SCSara Cuadrado-Castano
Sara Cuadrado-Castano
GPGvantsa Pantsulaia
Gvantsa Pantsulaia
KKKristy Kim
Kristy Kim
MAMark Aleynick
Mark Aleynick
JBJoshua D. Brody
Joshua D. Brody
Immunotherapies directly enhancing anti-tumor CD8+ T cell responses have yielded measurable but limited success, highlighting the need for alternatives. Anti-tumor T cell responses critically depend on antigen presenting dendritic cells (DC), and enhancing mobilization, antigen loading and activation of these cells represent an attractive possibility to potentiate T cell based therapies. Here we show that expansion of DCs by Flt3L administration impacts in situ vaccination with oncolytic Newcastle Disease Virus (NDV). Mechanistically, NDV activates DCs and sensitizes them to dying tumor cells through upregulation of dead-cell receptors and synergizes with Flt3L to promote anti-tumor CD8+ T cell cross-priming. In vivo, Flt3L-NDV in situ vaccination induces parallel amplification of virus- and tumor-specific T cells, including CD8+ T cells reactive to newly-described neoepitopes, promoting long-term tumor control. Cross-presenting conventional Type 1 DCs are indispensable for the anti-tumor, but not anti-viral, T cell response, and type I IFN-dependent CD4+ Th1 effector cells contribute to optimal anti-tumor immunity. These data demonstrate that mobilizing DCs to increase tumor antigen cross-presentation improves oncolytic virotherapy and that neoepitope-specific T cells can be induced without individualized, ex vivo manufactured vaccines.

1 November 2015 in Virus Research
Verified
Journal Article
Closed access
SCSara Cuadrado-Castano
Sara Cuadrado-Castano
MSMaria T. Sanchez-Aparicio
Maria T. Sanchez-Aparicio
AGAdolfo Garcia-Sastre
Adolfo Garcia-Sastre
EVEnrique Villar
Enrique Villar

5 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
NGNoemi Garcia
Noemi Garcia
IAIrina Palacin Aliana
Irina Palacin Aliana
SESusana Esteban-Rubio
Susana Esteban-Rubio
RMRodrigo Madurga
Rodrigo Madurga
SRSergio Rius-Rocabert
Sergio Rius-Rocabert
ÁAÁngel Ayuso-Sacido
Ángel Ayuso-Sacido
Glioblastoma (GBM) is the most aggressive and frequent primary brain tumor in adults with a median overall survival of 15 months. Tumor recurrence and poor prognosis are related to cancer stem cells (CSCs), which drive resistance to therapies. A common characteristic in GBM is CDKN2A gene loss, located close to the cluster of type I IFN genes at Ch9p21. Newcastle disease virus (NDV) is an avian paramyxovirus with oncolytic and immunostimulatory properties that has been proposed for the treatment of GBM. We have analyzed the CDKN2A-IFN I gene cluster in 1018 glioma tumors and evaluated the NDV oncolytic effect in six GBM CSCs ex vivo and in a mouse model. Our results indicate that more than 50% of GBM patients have some IFN deletion. Moreover, GBM susceptibility to NDV is dependent on the loss of the type I IFN. Infection of GBM with an NDV-expressing influenza virus NS1 protein can overcome the resistance to oncolysis by NDV of type I-competent cells. These results highlight the potential of using NDV vectors in antitumor therapies.

1 March 2013 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
SCS Carrera
S Carrera
SCSara Cuadrado-Castano
Sara Cuadrado-Castano
JSJ Samuel
J Samuel
GJGeorge Jones
George Jones
EVE Villar
E Villar
SMSalvador Macip
Salvador Macip
Stra6 is the retinoic acid (RA)-inducible gene encoding the cellular receptor for holo-retinol binding protein. This transmembrane protein mediates the internalization of retinol, which then upregulates RA-responsive genes in target cells. Here, we show that Stra6 can be upregulated by DNA damage in a p53-dependent manner, and it has an important role in cell death responses. Stra6 expression induced significant amounts of apoptosis in normal and cancer cells, and it was also able to influence p53-mediated cell fate decisions by turning an initial arrest response into cell death. Moreover, inhibition of Stra6 severely compromised p53-induced apoptosis. We also found that Stra6 induced mitochondria depolarization and accumulation of reactive oxygen species, and that it was present not only at the cellular membrane but also in the cytosol. Finally, we show that these novel functions of Stra6 did not require downstream activation of RA signalling. Our results present a previously unknown link between the RA and p53 pathways and provide a rationale to use retinoids to upregulate Stra6, and thus enhance the tumour suppressor functions of p53. This may have implications for the role of vitamin A metabolites in cancer prevention and treatment.

1 May 2015 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SCSara Cuadrado-Castano
Sara Cuadrado-Castano
JAJuan Ayllon
Juan Ayllon
MMMena Mansour
Mena Mansour
JIJanis de la Iglesia-Vicente
Janis de la Iglesia-Vicente
SJStefan Jordan
Stefan Jordan
EVEnrique Villar
Enrique Villar
Newcastle disease virus (NDV) is considered a promising agent for cancer therapy due to its oncolytic properties. These include preferential replication in transformed cells, induction of innate and adaptive immune responses within tumors, and cytopathic effects in infected tumor cells due to the activation of apoptosis. To enhance the latter and thus possibly enhance the overall oncolytic activity of NDV, we generated a recombinant NDV encoding the human TNF receptor Fas (rNDV-B1/Fas). rNDV-B1/Fas replicates to similar titers as its wild-type (rNDV-B1) counterpart; however, overexpression of Fas in infected cells leads to higher levels of cytotoxicity correlated with faster and increased apoptosis responses, in which both the intrinsic and extrinsic pathways are activated earlier. Furthermore, in vivo studies in syngeneic murine melanoma models show an enhancement of the oncolytic properties of rNDV-B1/Fas, with major improvements in survival and tumor remission. Altogether, our data suggest that upregulation of the proapoptotic function of NDV is a viable approach to enhance its antitumor properties and adds to the currently known, rationally based strategies to design optimized therapeutic viral vectors for the treatment of cancer. Mol Cancer Ther; 14(5); 1247–58. ©2015 AACR.

23 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGagandeep Singh
Gagandeep Singh
Juan García-Bernalt DiegoJuan García-Bernalt Diego
Juan García-Bernalt Diego
PWPrajakta Warang
Prajakta Warang
SPSeok-Chan Park
Seok-Chan Park
LCLauren Chang
Lauren Chang
MSMichael Schotsaert
Michael Schotsaert
Antigenically distinct SARS-CoV-2 variants increase the reinfection risk for vaccinated and previously exposed population due to antibody neutralization escape. COVID-19 severity depends on many variables, including host immune responses, which differ depending on genetic predisposition. To address this, we perform immune profiling of female mice with different genetic backgrounds –transgenic K18-hACE2 and wild-type 129S1– infected with the severe B.1.351, 30 days after exposure to the milder BA.1 or severe H1N1. Prior BA.1 infection protects against B.1.351-induced morbidity in K18-hACE2 but aggravates disease in 129S1. H1N1 protects against B.1.351-induced morbidity only in 129S1. Enhanced severity in B.1.351 re-infected 129S1 is characterized by an increase of IL-10, IL-1β, IL-18 and IFN-γ, while in K18-hACE2 the cytokine profile resembles naïve mice undergoing their first viral infection. Enhanced pathology during 129S1 reinfection cannot be attributed to weaker adaptive immune responses to BA.1. Infection with BA.1 causes long-term differential remodeling and transcriptional changes in the bronchioalveolar CD11c+ compartment. K18-hACE2 CD11c+ cells show a strong antiviral defense expression profile whereas 129S1 CD11c+ cells present a more pro-inflammatory response upon restimulation. In conclusion, BA.1 induces cross-reactive adaptive immune responses in K18-hACE2 and 129S1, but reinfection outcome correlates with differential CD11c+ cells responses in the alveolar space.